You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Dr. John Cush RheumNow
4 years 4 months ago
Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA
Dr. John Cush RheumNow
4 years 4 months ago
Acne with JAK Inhibitors
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.
https://t.co/b9pX9NgZAx https://t.co/RL9vi3Xbf6
Prevention of knee and hip osteoarthritis would obviate considerable disability and future surgery. We may be one step closer according to a prospective European GWAS study showing polygenic risk scores (PRSs) significantly associated with higher risks for knee and hip OA joint replacement.
Dr. John Cush RheumNow
4 years 4 months ago
Prospective randomized trial of ultrasound-guided genicular nerve block (GNB) vs physical therapy (PT) i102 pts chronic knee #OA - GNB was superior at walk distance, pain, functional and physical capacity, at 12 weeks https://t.co/MOJ16zAiqH https://t.co/JJJye2dobH
Previously quoted average delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years.
Dr. John Cush RheumNow
4 years 4 months ago
Expansive (full read) review of CBD - legal and regulatory overview, availability, physiologic and pharmacologic effects, safety, & risks, standards, use in specific rheumatic disorders. https://t.co/hefwKTmPLK https://t.co/IZKZMOZ5ij
Dr. John Cush RheumNow
4 years 4 months ago
TOMORROW! Register for our 5/10 Tuesday Night Rheumatology on PsA Advances.
This webinar will feature highlights from:
PsA Guidelines
Arthur Kavanaugh, MD
Drug Targeting in PsA
Bruce Kirkham, MD
PsA Registries and Real World Data
Alexis Ogdie, MD
https://t.co/0fNuHz6wVy https://t.co/KssNJ41Wqz
Dr. John Cush RheumNow
4 years 4 months ago
DOCTORS: are you ready to attend big medical meetings ? @LCalabreseDO
Dr. John Cush RheumNow
4 years 4 months ago
Allopurinol Use Does Not Increase Mortality in Gout w/ Chronic Kidney Disease
A trial has shown that allopurinol use dose escalation and achieving target uric acid levels, was not associated w/ increased mortality in patients with gout and concurrent CKD.
https://t.co/8LHlRyTgS0 https://t.co/4Hu9cTwptO
Dr. John Cush RheumNow
4 years 4 months ago
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/U5wAQdWLdC https://t.co/QfoaogDeun
Dr. John Cush RheumNow
4 years 4 months ago
TLR7 signaling impt to SLE as it drives type I IFN & activation of autoreactive B cells. Nature reports missense TLR7 (Y264H) variant from severe lupus induces guanosine & cGMP & causes murine lupus when introduced into mice. https://t.co/VZioZfcJQ6 https://t.co/AtxWD4XGBF
Dr. John Cush RheumNow
4 years 4 months ago
Good free patient info handout on LUMBAR SPINAL STENOSIS from JAMA https://t.co/aDPwLzFvfQ
Dr. John Cush RheumNow
4 years 4 months ago
Phase 2b DBRPCT of Intranodular injections of adalimumab in 140 pts w/ Dupuytrens contracture showed signif reduction nodule size and hardness ((−4·6 vs −2·2; p=0·0002) at 12 months https://t.co/9wBOeQNUdL https://t.co/HOR8rzYuRa
Dr. John Cush RheumNow
4 years 4 months ago
Dr. Judith James on environmental factors that contribute to lupus risk and expression. #UTSWSLE2022 https://t.co/MGE51vlDMY
